EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.
| Revenue (TTM) | $2.79M |
| Gross Profit (TTM) | $-257.47M |
| EBITDA | $-314.38M |
| Operating Margin | -450.70% |
| Return on Equity | -148.70% |
| Return on Assets | -74.90% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.40 |
| Price-to-Book | 7.65 |
| Price-to-Sales (TTM) | 150.59 |
| EV/Revenue | 398.79 |
| EV/EBITDA | 11.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 161.70% |
| Shares Outstanding | $86.21M |
| Float | $66.83M |
| % Insiders | 3.58% |
| % Institutions | 111.22% |
Volatility is currently expanding
EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.
EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transcript
EyePoint said on Monday its experimental eye drug failed to meet its main goal in a late-stage trial.
– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD; primary endpoint not achieved in full dataset, confounded by this asymmetric cohort – – LUGANO demonstrated clinically meaningful results that reinforce DURAVYU's potential to improve the treatment paradigm in wet AMD, with compelling key secondary endpoints, including reduction in treatment burden, supplement-free rates, favorable safety profile with redosing, and strong anatomic control through Week 56 compared to on-label aflibercept – – 42% reduction in treatment burden achieving superiority versus on-label aflibercept (nominal p-value of
WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
EyePoint (EYPT) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $0.85 per share a year ago.
– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 –– – Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 –– – Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 –– – $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027 –– WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the second quarter ended June 30, 2026, and highlighted recent corporate developments.
– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients ––
EyePoint (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EYPT and any ticker you trade — then tracks every position and per-strategy win rate.
